Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MLN-4760 is an angiotensin-converting (ACE2) inhibitor(human ACE2;IC50=0.44 nM). It also has excellent selectivity (<5000-fold) versus related enzymes including human testicular ACE (IC50, <100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 187.00 | |
5 mg | In stock | $ 397.00 | |
10 mg | In stock | $ 597.00 | |
25 mg | In stock | $ 953.00 | |
50 mg | In stock | $ 1,290.00 | |
100 mg | In stock | $ 1,730.00 |
Description | MLN-4760 is an angiotensin-converting (ACE2) inhibitor(human ACE2;IC50=0.44 nM). It also has excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
Targets&IC50 | ACE2 (human):0.44 nM (IC50), Carboxypeptidase A (bovine):27 μM (IC50) |
In vitro | MLN-4760 displays pIC50 at rhACE2 of 8.5±0.1 and at rhACE of 4.4±0.2. MLN-4760 also shows pIC50 at rhACE2 of 4.7±0.1, 6.9±0.1, and an ACE of 4.4±0.1, 6.2±0.1 in murine heart and mononuclear cells (MNCs), respectively. MLN-4760 potently quenches the cleavage of the 7-Mca-YVADAPK(Dnp) in rhACE2[2]. |
In vivo | MLN-4760 (100 μM, intracerebroventricular infusion for five days) obviously worsens neurological function at 4 h and 3 d post-stroke. However, without obviously increasing infarct volume[3]. |
Molecular Weight | 428.31 |
Formula | C19H23Cl2N3O4 |
CAS No. | 305335-31-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 199 mg/mL(464.62 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MLN-4760 305335-31-3 Endocrinology/Hormones RAAS inhibit Angiotensin-converting Enzyme (ACE) MLN 4760 Inhibitor MLN4760 inhibitor